Cargando…

The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes

OBJECTIVE: Molecular imaging of nigrostriatal dopamine transporters (DAT) and sympathetic cardiac innervation with single-photon emission computed tomography (SPECT) are useful tools for differentiating idiopathic Parkinson disease (PD) from other degenerative parkinsonian syndromes (non-PD). Nevert...

Descripción completa

Detalles Bibliográficos
Autores principales: Uyama, Naoto, Otsuka, Hideki, Shinya, Takayoshi, Otomi, Yoichi, Harada, Masafumi, Sako, Wataru, Izumi, Yuishin, Kaji, Ryuji, Watanabe, Yuya, Takashi, Satoru, Kunikane, Yamato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433627/
https://www.ncbi.nlm.nih.gov/pubmed/28410288
http://dx.doi.org/10.1097/MNM.0000000000000674
_version_ 1783236885793996800
author Uyama, Naoto
Otsuka, Hideki
Shinya, Takayoshi
Otomi, Yoichi
Harada, Masafumi
Sako, Wataru
Izumi, Yuishin
Kaji, Ryuji
Watanabe, Yuya
Takashi, Satoru
Kunikane, Yamato
author_facet Uyama, Naoto
Otsuka, Hideki
Shinya, Takayoshi
Otomi, Yoichi
Harada, Masafumi
Sako, Wataru
Izumi, Yuishin
Kaji, Ryuji
Watanabe, Yuya
Takashi, Satoru
Kunikane, Yamato
author_sort Uyama, Naoto
collection PubMed
description OBJECTIVE: Molecular imaging of nigrostriatal dopamine transporters (DAT) and sympathetic cardiac innervation with single-photon emission computed tomography (SPECT) are useful tools for differentiating idiopathic Parkinson disease (PD) from other degenerative parkinsonian syndromes (non-PD). Nevertheless, these modalities are often insufficient for achieving a definite diagnosis. The aims of this study were to evaluate the diagnostic accuracy of the combination of these tools. MATERIALS AND METHODS: The SPECT radiotracers [(123)I]-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)-nortropane (FP-CIT) and meta-[(123)I]-iodobenzylguanidine (MIBG) were used to research presynaptic dopaminergic projections (DAT SPECT) and myocardial adrenergic innervation (MIBG scintigraphy), respectively. PD patients (n=15; age: 61.5±13.6 years) and non-PD patients (n=19; age: 62.6±14.2 years) who underwent both tests were enrolled in this study. Receiver-operating characteristic analyses were used to set the cutoff values of the specific binding ratio in DAT SPECT and the heart to mediastinum ratio in delayed scan in MIBG scintigraphy for differentiating PD from non-PD. We calculated the sensitivity, specificity, and test accuracy of the individual methods and also the combination of these two modalities. RESULTS: When DAT SPECT and MIBG scintigraphy were used individually, they showed mild accuracy in differentiating PD from non-PD (DAT, 67.6%; MIBG, 67.6%). The combination of the two approaches using cutoff values of less than 3.24 for the specific binding ratio and less than 2.745 for the delayed heart to mediastinum ratio enabled more accurate differentiation between PD and non-PD. The accuracy of these indices in distinguishing PD from non-PD was 79.4%. CONCLUSION: These results suggested that the combination of DAT SPECT and MIBG scintigraphy may improve the diagnostic accuracy in differentiating PD from non-PD.
format Online
Article
Text
id pubmed-5433627
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-54336272017-05-23 The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes Uyama, Naoto Otsuka, Hideki Shinya, Takayoshi Otomi, Yoichi Harada, Masafumi Sako, Wataru Izumi, Yuishin Kaji, Ryuji Watanabe, Yuya Takashi, Satoru Kunikane, Yamato Nucl Med Commun Original Articles OBJECTIVE: Molecular imaging of nigrostriatal dopamine transporters (DAT) and sympathetic cardiac innervation with single-photon emission computed tomography (SPECT) are useful tools for differentiating idiopathic Parkinson disease (PD) from other degenerative parkinsonian syndromes (non-PD). Nevertheless, these modalities are often insufficient for achieving a definite diagnosis. The aims of this study were to evaluate the diagnostic accuracy of the combination of these tools. MATERIALS AND METHODS: The SPECT radiotracers [(123)I]-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)-nortropane (FP-CIT) and meta-[(123)I]-iodobenzylguanidine (MIBG) were used to research presynaptic dopaminergic projections (DAT SPECT) and myocardial adrenergic innervation (MIBG scintigraphy), respectively. PD patients (n=15; age: 61.5±13.6 years) and non-PD patients (n=19; age: 62.6±14.2 years) who underwent both tests were enrolled in this study. Receiver-operating characteristic analyses were used to set the cutoff values of the specific binding ratio in DAT SPECT and the heart to mediastinum ratio in delayed scan in MIBG scintigraphy for differentiating PD from non-PD. We calculated the sensitivity, specificity, and test accuracy of the individual methods and also the combination of these two modalities. RESULTS: When DAT SPECT and MIBG scintigraphy were used individually, they showed mild accuracy in differentiating PD from non-PD (DAT, 67.6%; MIBG, 67.6%). The combination of the two approaches using cutoff values of less than 3.24 for the specific binding ratio and less than 2.745 for the delayed heart to mediastinum ratio enabled more accurate differentiation between PD and non-PD. The accuracy of these indices in distinguishing PD from non-PD was 79.4%. CONCLUSION: These results suggested that the combination of DAT SPECT and MIBG scintigraphy may improve the diagnostic accuracy in differentiating PD from non-PD. Lippincott Williams & Wilkins 2017-06 2017-04-18 /pmc/articles/PMC5433627/ /pubmed/28410288 http://dx.doi.org/10.1097/MNM.0000000000000674 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CreativeCommonsAttribution-NonCommercial-NoDerivativesLicense4.0) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Articles
Uyama, Naoto
Otsuka, Hideki
Shinya, Takayoshi
Otomi, Yoichi
Harada, Masafumi
Sako, Wataru
Izumi, Yuishin
Kaji, Ryuji
Watanabe, Yuya
Takashi, Satoru
Kunikane, Yamato
The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
title The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
title_full The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
title_fullStr The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
title_full_unstemmed The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
title_short The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
title_sort utility of the combination of a spect study with [(123)i]-fp-cit of dopamine transporters and [(123)i]-mibg myocardial scintigraphy in differentiating parkinson disease from other degenerative parkinsonian syndromes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433627/
https://www.ncbi.nlm.nih.gov/pubmed/28410288
http://dx.doi.org/10.1097/MNM.0000000000000674
work_keys_str_mv AT uyamanaoto theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT otsukahideki theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT shinyatakayoshi theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT otomiyoichi theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT haradamasafumi theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT sakowataru theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT izumiyuishin theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT kajiryuji theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT watanabeyuya theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT takashisatoru theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT kunikaneyamato theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT uyamanaoto utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT otsukahideki utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT shinyatakayoshi utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT otomiyoichi utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT haradamasafumi utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT sakowataru utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT izumiyuishin utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT kajiryuji utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT watanabeyuya utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT takashisatoru utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes
AT kunikaneyamato utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes